New gene discovered drives cancer drug resistance
Scientists in Salford, UK, have identified a gene which is ‘revving the engine of cancer’ against the world’s most common breast cancer drug.
List view / Grid view
Scientists in Salford, UK, have identified a gene which is ‘revving the engine of cancer’ against the world’s most common breast cancer drug.
Repositive, the company that created the world’s largest portal for accessing human genomic research data, has closed a Series A funding round of £2.5 million.
Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model...
A research team from Instituto Gulbenkian de Ciencia (IGC, Portugal), developed a new genetic technique that allows the elimination of specific neurons of the peripheral nervous system without affecting the brain.
Enables real-time measurements of cell health, proliferation, movement and function while cells remain unperturbed in a physiologically relevant environment...
The IntelliCyt Cy-Clone™ PLUS Assay System will accelerate and improve the quality of clone ranking and selection for developing cell lines which can reduce production costs of biopharmaceuticals...
Researchers from UPM and CSIC have employed waste from the agri-food industry to develop biomaterials that are able to act as matrices to regenerate bone and cartilage tissues, which is of great interest for the treatment of diseases related to ageing.
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
Plasticell, a developer of stem cell technologies and cell-based therapies, has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
The University of Glasgow has officially opened its new £32M Imaging Centre of Excellence (ICE).
Nexeon MedSystems has licensed a portfolio of patents from Marathon Patent Group. The portfolio of 86 patents originated from Siemens AG, one of the world’s preeminent engineering companies.
Researchers have found that cannabinoid-based therapies have unique anti-bacterial properties that fight MSRA and other infectious bacteria.
Researchers have shed light on genome reorganisation occurring during the first hours post-fertilisation in a single-cell mammalian embryo
Growth of colorectal cancer cells can be inhibited with the odorant troenan.
Screening for prostate cancer is controversial. It can save lives, but it can also lead to unnecessary diagnoses, followed by surgical or radiation procedures, which themselves may lead to severe side-effects.